<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03213886</url>
  </required_header>
  <id_info>
    <org_study_id>VITAMINA_D</org_study_id>
    <secondary_id>2017-001778-40</secondary_id>
    <nct_id>NCT03213886</nct_id>
  </id_info>
  <brief_title>The Effect of Supplementation of Vitamin D Deficiency in Older People With Acute Hip Fracture:</brief_title>
  <acronym>VITAMINA_D</acronym>
  <official_title>A Prospective Randomized Trial Comparing the Effects of 2 Vitamin D Supplementation Regimens in Elderly People After Hip Fracture Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leonor Cuadra Llopart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundacio Salut i Envelliment UAB</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Consorci Sanitari de Terrassa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be done to evaluate the effect of load dose of vitamin D compared to the dose&#xD;
      of usual clinical practice, in improving mobility and reducing disability in older people&#xD;
      following a hip fracture.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hip fractures and related disabilities are important public health issues for elderly people&#xD;
      around the world. Attending the progressive aging of the population, an increase in the&#xD;
      number of hip fractures is expected. In fact, some studies estimate that, globally, the&#xD;
      incidence will exceed 6 million in 2050. In Spain, approximately 33,000 hip fracture occur&#xD;
      annually, with an overall incidence of 517 cases per 100,000 elderly people. 90% occur in&#xD;
      people over 64 years of age and the incidence increases exponentially beyond 80 years (&gt; 64:&#xD;
      97/100000 inhabitants-year;&gt; 85: 1898/100000 inhabitants-year).&#xD;
&#xD;
      Regarding the functional prognosis, those patients who survive the episode of the fracture&#xD;
      often suffer a functional impairment. Outcomes for people who survive hip fracture are of&#xD;
      concern, with more than one-quarter dying within a two-year period, and most of them not&#xD;
      recovering their previous functional level. More than 10 % of survivors will be unable to&#xD;
      return to their previous residence.&#xD;
&#xD;
      Vitamin D deficiency (serum 25 hydroxyvitamin D, 25OHD, level &lt; 30 ng/mL) is commonly&#xD;
      associated with hip fracture in elderly people. Without preventive treatment, however,&#xD;
      vitamin D deficiency following hip fracture may result in proximal muscle weakness, pain,&#xD;
      reduced dynamic balance and performance speed.&#xD;
&#xD;
      It is not clear how much Vitamin D must be taken in order to reach the optimal level.&#xD;
      Although the benefits of supplementing patients with at least 800 to 1000 units (U)/day&#xD;
      Vitamin D3 may be recognized, there is little information available to guide physicians&#xD;
      regarding the appropriate management of hip fracture patients who may be severely Vitamin D&#xD;
      deficient, specially in acute hip fracture patients.&#xD;
&#xD;
      A randomized controlled trial, including 50 older adults (aged 75 or over) who having&#xD;
      suffered a hip fracture and with vitamin D deficiency, will be carried out. After surgical&#xD;
      treatment, participants with vitamin D deficiency (25OHD &lt; 30 ng/mL) will be randomly&#xD;
      allocated to an intervention group or control group. For the intervention group, participants&#xD;
      will receive 16.000 U Calcifediol oral daily along 5 days. For the control group will receive&#xD;
      16.000 U Calcifediol oral weekly along 5 weeks.&#xD;
&#xD;
      Functional status will be evaluated using Barthel Index, as well the proportion of patients&#xD;
      reaching an optimal level of 25OHD (&gt; 30 ng/mL) will be determined at discharge from hospital&#xD;
      (1 month approximately), 3, 6 and 12 months of follow up.&#xD;
&#xD;
      Secondary measures include the Timed Up and Go test, gait speed test, Short Physical&#xD;
      Performance Battery to compare the effect of the Vitamin D supplementation strategies on&#xD;
      functional and muscle strength scales. In addition, to measure the strength and muscle mass&#xD;
      will be used handheld dynamometer and bioimpedance analysis respectively&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">July 30, 2020</completion_date>
  <primary_completion_date type="Actual">April 20, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional gain</measure>
    <time_frame>at 6 months of follow up</time_frame>
    <description>Defined as a 15-point improvement in the Barthel Index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement serum Vitamin D (25OHD) levels</measure>
    <time_frame>at baseline, 1, 3, 6 and 12 months of follow-up.</time_frame>
    <description>Defined as a vitamin D levels &gt; 30 ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of muscle strength</measure>
    <time_frame>at 3, 6 and 12 months of follow up.</time_frame>
    <description>Using handheld dynamometer to measure (kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of muscle mass</measure>
    <time_frame>at 3, 6 and 12 months of follow up.</time_frame>
    <description>Using bioimpedance analysis to measure (kg)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Hip Fracture</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Calcifediol (Vitamin D) loading-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the intervention group will receive calcifediol16.000 units (U) /day for five days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcifediol (Vitamin D) at clinical practice dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in the control group will receive 16.000 U / week for five weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcifediol (Vitamin D)</intervention_name>
    <description>After surgical treatment, participants with vitamin D deficiency (25OHD &lt; 30 ng/mL) will be randomly allocated to an intervention group or control group.&#xD;
For the intervention group, participants will receive 16. 000 U oral Calcifediol daily for 5 days.&#xD;
For the control group, participants will receive 16.000 U oral Calcifediol weekly for 5 weeks.&#xD;
Both groups:&#xD;
Will follow the usual hip fracture rehabilitation pathway.&#xD;
25OHD serum levels will be measured after 4 weeks. Depending on the serum 25OHD level, the patients will receive different vitamin D strategies (according to the protocol) Patients will be monitored for up to 12 months after the discharge from the hospital, with 3 clinic visits at 3, 6 and 12 months (to determine serum vitamin D levels and to evaluate functional status)</description>
    <arm_group_label>Calcifediol (Vitamin D) at clinical practice dose</arm_group_label>
    <arm_group_label>Calcifediol (Vitamin D) loading-dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Patients aged 75 years or over with fragility hip fracture (requiring&#xD;
        surgical treatment) and vitamin D deficiency; able to provide informed consent, either&#xD;
        directly or via the person responsible.&#xD;
&#xD;
        Definitions:&#xD;
&#xD;
          -  Fragility hip fracture: understood as such those that are produced by trauma of low&#xD;
             intensity (for example, falls from the own height in standing or smaller)&#xD;
&#xD;
          -  Vitamin D deficiency: 25OHD serum levels &lt; 30 ng / mL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of severe functional dependence prior to fracture of the femur (Barthel Index&#xD;
             &lt; 35 points)&#xD;
&#xD;
          -  Diagnosis of dementia to a moderate degree (defined on &quot;Global Deterioration Scale&quot;&#xD;
             (GDS) and &quot;Functional Assessment Staging&quot; (FAST), GDS-FAST &gt; 5).&#xD;
&#xD;
          -  Medical conditions that contraindicate receiving vitamin D supplementation:&#xD;
             hypercalcemia (calcemia&gt; 10.5 mg / dL), hyperparathyroidism; chronic renal failure&#xD;
             with glomerular filtration rate (GFR) &lt;30 mL / min, calcium lithiasis; pathologies&#xD;
             with risk of hypercalcemia (tuberculosis, sarcoidosis ...), as well as pathologies&#xD;
             involving intestinal malabsorption.&#xD;
&#xD;
          -  Hypersensitivity to the active substance or to any of the excipients.&#xD;
&#xD;
          -  Use of drugs that interact with the use of vitamin D and with the risk of causing&#xD;
             hypercalcemia (phenytoin, phenobarbital, primidone, digoxin).&#xD;
&#xD;
          -  Reduced life expectancy (&lt;12 months) due to the presence of advanced concomitant or&#xD;
             end-of-life conditions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Consorci Sanitari de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08227</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Duque G, Daly RM, Sanders K, Kiel DP. Vitamin D, bones and muscle: myth versus reality. Australas J Ageing. 2017 Mar;36 Suppl 1:8-13. doi: 10.1111/ajag.12408. Review.</citation>
    <PMID>28297132</PMID>
  </reference>
  <reference>
    <citation>Hill TR, Aspray TJ. The role of vitamin D in maintaining bone health in older people. Ther Adv Musculoskelet Dis. 2017 Apr;9(4):89-95. doi: 10.1177/1759720X17692502. Epub 2017 Feb 14. Review.</citation>
    <PMID>28382112</PMID>
  </reference>
  <reference>
    <citation>Dawson-Hughes B. Vitamin D and muscle function. J Steroid Biochem Mol Biol. 2017 Oct;173:313-316. doi: 10.1016/j.jsbmb.2017.03.018. Epub 2017 Mar 22. Review.</citation>
    <PMID>28341251</PMID>
  </reference>
  <reference>
    <citation>Laiz A, Malouf J, Marin A, Longobardi V, de Caso J, Farrerons J, Casademont J. Impact of 3-Monthly Vitamin D Supplementation Plus Exercise on Survival after Surgery for Osteoporotic Hip Fracture in Adult Patients over 50 Years: A Pragmatic Randomized, Partially Blinded, Controlled Trial. J Nutr Health Aging. 2017;21(4):413-420. doi: 10.1007/s12603-016-0773-3.</citation>
    <PMID>28346568</PMID>
  </reference>
  <reference>
    <citation>Mak JC, Mason RS, Klein L, Cameron ID. An initial loading-dose vitamin D versus placebo after hip fracture surgery: randomized trial. BMC Musculoskelet Disord. 2016 Aug 11;17:336. doi: 10.1186/s12891-016-1174-9.</citation>
    <PMID>27515154</PMID>
  </reference>
  <reference>
    <citation>Sprague S, Petrisor B, Scott T, Devji T, Phillips M, Spurr H, Bhandari M, Slobogean GP. What Is the Role of Vitamin D Supplementation in Acute Fracture Patients? A Systematic Review and Meta-Analysis of the Prevalence of Hypovitaminosis D and Supplementation Efficacy. J Orthop Trauma. 2016 Feb;30(2):53-63. doi: 10.1097/BOT.0000000000000455. Review.</citation>
    <PMID>26429406</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 27, 2017</study_first_submitted>
  <study_first_submitted_qc>July 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2017</study_first_posted>
  <last_update_submitted>January 31, 2021</last_update_submitted>
  <last_update_submitted_qc>January 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Consorci Sanitari de Terrassa</investigator_affiliation>
    <investigator_full_name>Leonor Cuadra Llopart</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>hip fracture</keyword>
  <keyword>elderly</keyword>
  <keyword>vitamin D</keyword>
  <keyword>rehabilitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Calcifediol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

